<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343012">
  <stage>Registered</stage>
  <submitdate>2/06/2011</submitdate>
  <approvaldate>3/06/2011</approvaldate>
  <actrnumber>ACTRN12611000569909</actrnumber>
  <trial_identification>
    <studytitle>Oral Silodosin on Lower Urinary Tract Symptoms Due to Double-J stent: A Prospectively Randomized Study</studytitle>
    <scientifictitle>Oral silodosin on lower urinary tract symptoms due to double-J stent</scientifictitle>
    <utrn>U1111-1121-8585</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>urinary symptoms assosciated with indwelling double-J ureteral stents</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>daily oral silodosin 4 mg for 2 weeks in improving symptoms and quality of life in patients with indwelling double-J ureteral stents using specific questionnaire</interventions>
    <comparator>daily oral lactose tablet for 2 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ureteral stent symptom questionnaire (USSQ) evaluating the symptoms associated with double-J stents</outcome>
      <timepoint>at 2nd week and 4th week</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>quality of life of International Prostate Symptom Scale (IPSS) evaluating the symptoms associated with double-J stents</outcome>
      <timepoint>at 2nd week and 4th week</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients, with insertion of a double-J ureteral stent after ureteroscopic stone removal, were enrolled into the study</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>benign prostatic hyperplasia-related lower urinary symptoms(International Prostate Symptom Score greater greater than 7); a history of interstitial cystitis, chronic cystitis, chronic prostatitis, or stent insertion; and chronic medication with alpha-blockers or analgesics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>random numbers table</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate>30/04/2012</anticipatedenddate>
    <actualenddate>30/04/2012</actualenddate>
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Chung Jing Wang</primarysponsorname>
    <primarysponsoraddress>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</primarysponsoraddress>
    <primarysponsorcountry>Taiwan, Province Of China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Chung Jing Wang</fundingname>
      <fundingaddress>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</fundingaddress>
      <fundingcountry>Taiwan, Province Of China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>a randomized double-blinded controlled study to evaluate the effect of silodosin in improving symptoms and quality of life in patients with indwelling double-J ureteral stents using specific questionnaire</summary>
    <trialwebsite />
    <publication>not yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IRB STM</ethicname>
      <ethicaddress>60058 No 565 2nd Rd Ta-Ya Chia-Yi city,Taiwan ROC
St Martin De Porres Hospital</ethicaddress>
      <ethicapprovaldate>21/07/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>28/06/2010</ethicsubmitdate>
      <ethiccountry>Taiwan, Province Of China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd  Ta-Ya Rd, Chia-Yi city,Taiwan,ROC
St Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax />
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>